<SEC-DOCUMENT>0001615219-21-000054.txt : 20210520
<SEC-HEADER>0001615219-21-000054.hdr.sgml : 20210520
<ACCEPTANCE-DATETIME>20210520075740
ACCESSION NUMBER:		0001615219-21-000054
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210519
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20210520
DATE AS OF CHANGE:		20210520

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Salarius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001615219
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465087339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36812
		FILM NUMBER:		21942398

	BUSINESS ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021
		BUSINESS PHONE:		346-772-0346

	MAIL ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Flex Pharma, Inc.
		DATE OF NAME CHANGE:	20140730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>salarius-8k05192021.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7b058611bf754438b01b679821362382_1"></div><div style="min-height:31.5pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.600%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.600%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form 8-K </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.600%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                 Current Report </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Date of earliest event reported)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#58; May 19, 2021 </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.600%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"> SALARIUS PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.600%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.600%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Delaware</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(State or other jurisdiction</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of incorporation)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">001-36812</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Commission File Number)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">46-5087339</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(IRS Employer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Identification No.)</font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2450 Holcombe Blvd., Suite X, Houston, Texas 77021</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices, with zip code)</font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(832) 834-6992</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">N&#47;A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.600%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below)&#58; </font></div><div><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></div><div><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></div><div><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></div><div><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act&#58;</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.600%"><tr><td style="width:1.0%"></td><td style="width:37.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol(s)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Stock, par value $0.0001</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SLRX</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nasdaq Capital Market</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).Emerging growth company&#160;&#9744;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#9744;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.600%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.5pt;width:100%"><div><font><br></font></div></div><div style="padding-right:9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01&#160;&#160;&#160;&#160;    Other Events.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 19, 2021, Salarius Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release entitled &#34;Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting&#34; A copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.600%"><tr><td style="width:1.0%"></td><td style="width:8.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</font></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br>Number</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="salarius-xascoabstractsrel.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Press release issued by Salarius Pharmaceuticals, Inc. date</a><a href="salarius-xascoabstractsrel.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">d</a><a href="salarius-xascoabstractsrel.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> May 19, 2021 entitled &#34;Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting&#34;</a></font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-right:9pt;text-indent:0.36pt"><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><div id="i7b058611bf754438b01b679821362382_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 20, 2021 </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.641%"><tr><td style="width:1.0%"></td><td style="width:33.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:49.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALARIUS PHARMACEUTICALS, INC.</font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; David J. Arthur</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David J. Arthur </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Office</font></div></td></tr></table></div><div style="margin-bottom:7.1pt;padding-right:19.25pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:12pt;text-align:right"><font><br></font></div><div style="padding-right:12pt;text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>salarius-xascoabstractsrel.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i76b73e7713974284aca68746f1b456f6_1"></div><div style="min-height:72pt;width:100%"><div><img alt="image_01.jpg" src="image_01.jpg" style="height:55px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Preliminary drug activity observed in both relapsed&#47;refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Presentations include full data from dose-escalation stage of Phase 1&#47;2 clinical trial evaluating seclidemstat in Ewing sarcoma and preliminary data from ongoing AST trial  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HOUSTON, May 19, 2021 (GLOBE NEWSWIRE) &#8211; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Salarius Pharmaceuticals, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Nasdaq&#58; SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today the publication by the American Society of Clinical Oncology (ASCO) of three abstracts accepted for poster presentations during the ASCO 2021 Annual Meeting. ASCO 2021 will take place June 4-8, 2021 via a virtual platform. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Salarius submitted three abstracts disclosing clinical research involving its lead drug candidate, seclidemstat. Details on the presentations can be found below. Key findings include data showing that </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">seclidemstat has a manageable safety profile with no significant hematological toxicities, which can be a limitation for other LSD1 inhibitors. In addition, seclidemstat showed proof-of-concept preliminary drug activity in relapsed&#47;refractory Ewing sarcoma and other advanced cancer patients, including FET-rearranged sarcomas, at or below the recommended phase 2 dose (RP2D), which was established to be 900 mg BID. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We are excited to have the opportunity to present clinical data regarding safety, dosing, and initial efficacy signals for seclidemstat during ASCO 2021,&#8221; said&#160;David Arthur, President and Chief Executive of&#160;Salarius Pharmaceuticals. &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the first time, we will report full data and the recommended Phase 2 dose from the recently completed dose-escalation stage of our Phase 1&#47;2 clinical trial in Ewing sarcoma.  We will also discuss in more detail the preliminary drug activity data observed in FET-rearranged sarcoma patients from our Advanced Solid Tumor (AST) trial that supports our continued development of seclidemstat as single-agent therapy in select sarcomas.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The full abstracts are available on</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ASCO&#8217;s 2021 </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Meeting Library</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Details from the Salarius abstracts are as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Abstract #11514&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed&#47;refractory Ewing sarcoma</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Session Type &#38; Title&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Poster Discussion Session, Sarcoma</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Presenting Author&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Damon R. Reed, M.D., H. Lee Moffitt Cancer Center &#38; Research Institute, Tampa, Florida.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date &#38; Time&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 4, 2021, 9 a.m. ET</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Key Information &#38; Findings&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Seclidemstat has a manageable safety profile with proof-of-concept preliminary activity in heavily pretreated patients with relapsed or refractory Ewing sarcoma.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">900 mg BID established as the RP2D </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">A patient dosed at 600 mg BID achieved a reduction in target lesions after 58 days (cycle 2) with further tumor shrinkage after 112 days (cycle 4) and 168 days (cycle 6) for a maximum 76% tumor shrinkage&#59; Coincident new non-target lesion appearance at end of cycle 2</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Two additional patients dosed at 600 mg BID and 900 mg BID had overall stable disease</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_01.jpg" src="image_01.jpg" style="height:55px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">No treatment-related deaths&#59; The most common (&#62;5%) Grade 3 treatment-related adverse events (TRAEs) were vomiting (15%), abdominal pain (11%), and hypokalemia (11%)&#59; One patient with Grade 3 pancreatitis reported elevated lipase, a Grade 4 adverse event (AE)&#59;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> No significant hematological TRAES (Grade 3 occurred in &#60;5% of patients)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Abstract #3073&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST)</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Session Type &#38; Title&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Poster Session, Developmental Therapeutics&#8212;Molecularly Targeted Agents and Tumor Biology</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Presenting Author&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sant P. Chawla, M.D., Sarcoma Oncology Research Center, Santa Monica, California</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date &#38; Time&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Friday, June 4, 2021, 9 a.m. ET</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Key Information &#38; Findings&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Seclidemstat has shown activity among advanced sarcoma patients with a manageable safety profile. Dose escalation is ongoing and preliminary clinical data supports further exploration in FET-translocated sarcomas as single agent and in combination therapy. Safety data will be presented after completion of Phase 1 dose-escalation.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">As of December 30, 2020, 19 patients were enrolled in AST trial, including patients with prostate ovarian, pancreatic, renal, cervical and breast cancer, as well as sarcomas&#59; Patients received a median of four prior systemic treatments</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">13 patients were evaluable for response after 58 days of treatment (cycle 2)&#59; 7 patients had best response of stable disease (SD) with median time to progression (TTP) of 4.3 months, including 3 patients with advanced FET-rearranged sarcomas</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">All 7 patients were dosed at 300 mg BID or 600 mg BID </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The most common Grade 3 TRAEs were gastrointestinal-related and included diarrhea (5.3%) and abdominal pain (5.3%)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">No treatment-related deaths and no Grade 4 TRAEs have been reported</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Abstract #TPS11577&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Session Type &#38; Title&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Poster Session, Sarcoma</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Presenting Author&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Damon Reed, M.D., H. Lee Moffitt Cancer Center &#38; Research Institute, Tampa, Florida.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date &#38; Time&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 4, 2021, 9 a.m. ET</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Key Information&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This is an ongoing dose-expansion study assessing seclidemstat at the RP2D (900 mg BID) in two cohorts&#58; a single-agent expansion in select sarcoma patients and a safety lead-in dose escalation and expansion of seclidemstat in combination with topotecan and cyclophosphamide (TC) in Ewing sarcoma patients. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The sarcoma cohort will enroll patients with myxoid liposarcoma or other select sarcomas with FET family translocations, including desmoplastic small round cell tumor (DSRCT)&#59; The trial will allow patients treated with one to three prior lines of therapy</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Ewing sarcoma cohort will allow patients treated with up to two prior lines of therapy</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Primary objective is safety and tolerability, and secondary objective is efficacy</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Recruiting patients across eight U.S. locations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This year, ASCO received and reviewed more than 5,400 abstracts for the 2021 Annual Meeting, the world&#8217;s largest gathering of physicians, biopharmaceutical companies, researchers, and investors to discuss cancer research and therapeutics. Information about the Annual Meeting may be accessed at </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;conferences.asco.org&#47;am&#47;registration</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_01.jpg" src="image_01.jpg" style="height:55px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Salarius Pharmaceuticals</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius&#8217; lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1&#47;2 clinical trial for relapsed&#47;refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1&#47;2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">salariuspharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or follow Salarius on Twitter and LinkedIn.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as &#8220;anticipate,&#8221; &#8220;potential,&#8221; &#8220;progress,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;will,&#8221; &#8220;aim,&#8221; &#8220;can,&#8221; &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;allow,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;goal,&#8221; &#8220;provide,&#8221; &#8220;able to,&#8221; &#8220;position,&#8221; &#8220;project,&#8221; &#8220;developing,&#8221; and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following&#58; the company&#8217;s growth strategy&#59; the value of seclidemstat as a potential treatment for Ewing sarcoma, Ewing-related sarcomas and other cancers&#59; the status and anticipated progress and milestones of the company&#8217;s clinical trials in Advanced Solid Tumors and Ewing sarcoma&#59; the expansion of the company&#8217;s clinical trials to include Ewing-related sarcomas&#59; the company&#8217;s belief as to being well-capitalized through the completion of its clinical trials for seclidemstat and beyond&#59; Salarius&#8217; goal to maximize the potential of seclidemstat&#59; and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Salarius developing seclidemstat for several cancers with high unmet medical need. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following&#58; the sufficiency of the company&#8217;s capital resources&#59; the ability of, and need for, the company to raise additional capital to meet the company&#8217;s business operational needs and to achieve its business objectives and strategy&#59; the company&#8217;s ability to project future capital needs and cash utilization and timing and accuracy thereof&#59; the ability of the company to access the remaining funding available under the CPRIT grant&#59; future clinical trial results and impact of results on the company&#59; that the results of studies and clinical trials may not be predictive of future clinical trial results&#59; the sufficiency of Salarius&#8217; intellectual property protection&#59; risks related to the drug development and the regulatory approval process&#59; the competitive landscape and other industry-related risks&#59; market conditions and regulatory or contractual restrictions which may impact the ability of Salarius to raise additional capital&#59; the possibility of unexpected expenses or other uses of Salarius&#8217; cash resources&#59; risks related to the COVID-19 outbreak&#59; and other risks described in Salarius&#8217; filings with the&#160;Securities and Exchange Commission, including those discussed in the company&#8217;s quarterly report on Form 10-Q for the quarter ended March 31, 2021 and in the company&#8217;s annual report on Form 10-K for the year ended December 31, 2020. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management&#8217;s assumptions and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image_01.jpg" src="image_01.jpg" style="height:55px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contact</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tiberend Strategic Advisors, Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maureen McEnroe, CFA&#47;Miriam Miller (investors)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(212) 375-2664 &#47; 2694</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">mmcenroe&#64;tiberend.com</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">mmiller&#64;tiberend.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Johanna Bennett (media relations)<br>(212)&#160;375-2686&#160;<br>jbennett&#64;tiberend.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #C <P# 2(  A$! Q$!_\0
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MU:;ISE!]#FP]55J49KJ.HI!2UD=(44TN <4;Q0 ZBDZTM ##]\4^HR#O%24
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M,_PC_9Y\):!?J4U/[.U[>(?^6<T[F5D_X#O"_P# :](\/ZJNHZSKD*]+.Y2
MGW\F-_\ V>OS3%-5:U2<=K_J>Y&:IJ$);O\ RN;_ %-,N9/*3=G %2CI7SY^
MW;\1[KX:?LV>([O3[E[34]2,>DVTT9PZ&8X<J?[PC$A'H17/3INK.--=3:4E
M%79\R_M4_P#!1;58M;O?"7PLN(K>WM&:*\\3,@D:60'#);J< *ISF0YR>@[G
MXKU[XJ^-O%-W)<ZOXPUV_F9B2TFH2@=<\ -@?@!5/P#X+U#XA^--"\+:0$_M
M'5KM+.W\S.U2W5F[X5<L<=E.*_4'P1_P30^$NB:)##K]KJ/B75/+'G7DU]+
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MT&?(7[(?[0?Q,\9_M(>"-&USQOJVIZ7=7,JSVEQ-N20""1AD8' *C\J_6,'
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MHZBDSQFD+@=2!0 ZBF[QZTN: %HIN]?44;U]10 ZBFAP>]+0 M%%% !1110
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M&JZW;M937]M&RV]M _RRG<P&YBFX #/7)-?G#I@"ZA9=@)HNO;YQ7UK\ ?\
M@GCXY\:ZF^I>/-/E\+:!;QNRV4T@^VWLF#M4*I/EIG&68Y]!SD>?-^P=\>HT
M+IX$8R*-RXU*U^]P1C]YZBM\-+!X6,J-.:^;)J*K4:FT?LA?<Z=-C_GF?_0:
M_GSN.(IN/[W]:_H#@6XFT%1-$4N6MQNBSDJQ7D9Z<&OQXF_8+^/#1RA? K'=
MNQ_Q,;7G.?\ II7E9/5ITO:<\DMM_F=&)A*7+8_7#X3_ /),O"/_ &!K/_T2
ME=?7,_#O3KG1_ GANPO8C!>6FF6UO-$3G:ZQ*K#(XX((R#735\W/XG8[ELCX
M3_X*M_\ )-/ _P#V&9/_ $0U>!?\$QCC]IR;_L7;S_T=;5]9_P#!0GX+^,_C
M5X'\*:?X,T4ZU=V6I/<7$8GCAV(8B <N0.I'3->0?L(?LO?$_P"#_P =I=?\
M7>&&TC2&T6YM!<&[AE_>M) RC".3R$;MVZ\U]-AZU-9;*FY+FUT^9P2A)UU)
M+0^FOVX/"5UXQ_9A\<VEE$T]Q;6JZ@L:#)802+*P'OM1J_'+PSXDU#PAXBTK
M7M)F$&I:9=17EK*0"JR1N&4D=P2!D=_I7] %U MQ;R1,@D1U*LI&0P[@_6OR
MV_:4_P"">/C#PGXHO=7^'&FOXB\*W,AE33H) +RQ).3&%./,C&?E*G('!' )
MG*<73IQ="J[)CQ-)R:G'H>_^&?\ @IY\-+SPG%<ZU8ZQIFN+$!-I\%KYRF3'
M.R3(&"?7'N*^"OVD_CQJ'[0_Q/N_$]U"UE811"TTVQ+!C;VZY(W'N[%F8X]0
M!P!5OPU^R'\8_%6JQ6%KX U6VD=MIN-006T$78EG<_7H#[ U[Y\7?^"=WBSP
MK\-/!>F^#=,7Q=XI:YN+C7[^*:.!%RB"*.,2,#Y:G?C@DG).,@#TJ4,#@JMX
MRU?GL82=:M&S6Q>_X)2\?$/Q[CMI5O\ ^CFKW;]N']L*Z^ ]BGA/PS:RMXQU
M2U,T6H31'R+*$G9YJDC$D@(("] <%N, \?\ \$]?V=OB%\%O&GBV^\9^'CHU
MK?:?#!;N;F*4.ZR$D81V['N!7T3^TC^S9X<_:-\')I.L[[/4;5FET[58%W2V
MDC#!P.-R-@!E)Y]C@CQL55H/'\\]8Z;>AUTXS5&RT9\A_LK?\%$[70=!M_"_
MQ7N;R=[4A+7Q*J&9I$R<+<*.=RY^^!R ,\@D_2/BC]O7X):#HTE[!XTMM9E"
MDI9:9$\LSGL,;<#_ ($17Y\?$7]@SXR?#S49HH/#A\5::"?+U'0G$@=1W:)B
M'0^V"/0FN$TS]F7XLZQ=BVM/AUXA>8]!)9F(#GNSD#\2:].>!P%>7M8SLO)H
MYU5K0]UHYSXJ>/9/B7\1O$_BZX@6P.KWTM[Y 8'R4)^52> <* ">^#ZU^NG[
M#/P_OOAQ^S3X2TW4XS#J%U'+J4L+##1_:)6E1"/4(Z @]\U\V?LQ?\$W;_3M
M9LO$OQ5-L4MW$UOX:MW$RLP/!N7^Z0"!^[7(/&2<8K]"X(O*4* %4#  Z"O.
MS7%TZD8T*+ND;8>E*+<Y;LGHHHKYX[@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ;BD<[:4GCBN/^)WQ$L?AKX2O-:OL,(ALA@!^::4\(@^I_E[5I3IS
MK35."NV<]:M3PU*5:J[1CJSBOV@OC9%\--'%C8.'\07B'R%P&$"]/,8?F #U
M.?0U\2SWLFHW$EQ<2M/<2L6DDD.6=B>23ZGUIOB?Q9J'C+Q!>:SJ<QGO+I]S
M-DX49X51_= P!_\ KJA%+S7[QDF40RN@D_C>[_3T/Y)XJS^MGN+<D[4X_"OU
M]67\8&:TO#GAO4?%FL0Z9I-L;S4)L^7"IQT'.3V'J3ZU2TFQN=9OH+&S@>YN
MKAA'%%&,LS'H /\ /?TKZ&\$?!/XJ> I;B?1&T6WFN %>29][X],E.!ZUU9E
MF-/!TW'GBIO;F=CRLDR:OF-=2=*4J:?O<JN_0_,/XD7NM3>-M73Q!:2Z;JUM
M,UM-8SKM:UV\"/!]  >,YZ@D5D:#X@O/"NMZ?K6G.8]1TVYCN[=P<$21L&7\
M#@ _C7Z.?&K]DKQA\5;^7Q-XGTK2]4U>VMF0MIDWE7%RJY*H1M =AR%W$=<9
MQ7Y_>/3X86[@A\.V6HV$L#/'=Q:@-K*P8 +M).",,"#T].*^052&)@Y>TC*7
M5)W/Z.P.*]G*&%IX6=.*V;225EZG[E_#WQ?:^/O!&A>)++BTU:RAO8@3G"R(
M& _#-=(.*\+_ &)+F6[_ &5_AT\IRZZ>8A[*LKJH_("O=#UK\MK0Y*DH=FS]
M"@^:*8FWFHS""<_XU-1619&L6T8!XJ2BB@ IC)N&#R,T^B@"+R13@N!U_&GT
M4 ,*<YI2#C%.HH C,>1S2A".]/HH 8R[J88,G^7-344 1B,^N*4(=N,T^B@!
M@0BEVG'6G44 ,52I[8I]%% # A!H,><'O3Z:6 [B@!U1O&6.>.F*DHH A$ 7
MO3]GKBGT4 ,"$8R<XI]%% $1BSW[YI/(&.3_ %J:BD BC I:**8!1110 444
M4 %%-W#.,\TZ@ HHHH **** "BBB@ HHII; YH =12!@U+0!'(VT$U\!_M3_
M !3?QSX^ETFUFW:1HS- @!^66;_EH_X8"CKT;UK[-^+'BO\ X0KX>>(=9W;'
MM+*1XV)_Y:$80?BQ%?EZUPTDCLSM([,2SL>6/<D^^<_C7Z'PA@8U:LL7-?#H
MO7_AOS/R#Q!S*5*A# TW\>K]%L:*2X[\58BDR<#&<XP3U/UZ?G6;&Y8X'/3@
M5]>? ;]EFPN_#?\ :WC6Q>>[O0&@L'<IY$?8MC^)NI!Z# ]:_1,RS2AEE+VE
M9[[+J?C>3Y#BLZK^RPZVW;V1=_9[T'P+\.;0:OK7BC0Y?$4ZX(-_%_HJ'J@^
M;[WJ?PZ=?<1\7/ ^>/%FC?\ @?%_\57*)^RW\.E48T!1_P!MY/\ XJG#]F'X
M=CC^PA_W_D_^*K\=Q=? XVM*O6J3;?DO\S^ALNP6:Y5AXX7"TJ2BO.7WO3<Z
MAOBYX*/_ #->C_\ @?%_C7YU_P#!0#X.:!?>*H?B#X!O+#5'U1Q#K&F:7*DC
MB<#*W(13T8 !R!UVD\L<_> _9E^'8'_("7'_ %WD_P#BJ\B_:=\#^ /A!\,K
MV\LM'2+6[X_8K#]\^1(P.Y_O?P+N;IZ>M;9;]2CB81H2FY/2UE_F:8W$9U1H
M2JU84THZ[R_R/2?V-K0V'[,W@*W/WH[$JWU\Q\_K4/QG^+GB[P?X\T+PYX7T
MVTU*YU.!G2*Y.TLX8\ [@!P.]:7[)I_XQ[\&_P#7L_\ Z->N7^*I _:<^&OK
MY4O_ +/7/2IPEF-:,XW2YW9^5S;'XBLLKH2IR<92<%=;ZM)_F5;WXG_'+08#
M>ZAX"LI;.(;I1;3"1\8YX21CT] :]1^#_P 6[#XM:"U]:QM:W,#".ZLY,;HG
MZCZ@]0?J, BN[*H8R2!TZFOG#X)(EG^T?\2[73<+I@4,RI]U9-P)XZ?>:2LT
MZ.-P]5JDH2@KW5]=4K.[?<5L3E>,H0=>52%1M-2M=.UTTTEVU/1OC_\ $K4O
MA=X*75]+AAGN#=1P;;@$KA@V>ASV%>A:7<R75C;RR$;GB5FQTR1GBO$OVR>?
MA1%_V$(?_07KVK1W4:=:Y8?ZI<\^U<=2E!8*G42U<I?A8].AB*CS2O1E+W5&
M#2]>:_Y'FO[0_P 5=5^%'AK3-1TJ"VGFN;Y;9EN02H4H[=CG^$5ZK;N9(8V;
M&2H)QZU\\?MKNK> ]"P0?^)JG3_KE+7T+:_ZB+_<'\J=>E".#HU$M6Y7^5K$
MX3$U)YGB:,I7C%0LNU[W%N)A$,YQ@9_"O"?A'^T1<_$+XHZUX>N(K>+3E,S:
M;*BD/,L;[><G!)4YX'8UWGQQ\7_\(/\ #+7M54[9EMFA@.>?-<A$/X%L_A7S
MQ>^&S\'M$^#OBN6,Q203&/4G P0L^9"&]=JF0?A7;E^%I5J$W47O2TCZI7_R
M7S/+SK,<1A\725!^["TI^C:C_F_D?8JDXKS;X[_$34?ACX!N-<TV.&:YCGBB
M$=P"5(9L'H0?UKT2U<21*P(8$ Y'3\*\5_;!'_%EK[_KZM__ $8*\[+Z<:N+
MI4ZBNFU?[SW,XK3HY=6JTG:2BVG\CG['XD?';4M/AOK;P3I<MM-&LT;K<I\R
MD9''FYZ=L5T7PJ_: NO%'BE_"?BK26\-^)E!*6\F=LV.2!GD'&2.H(S@\5Z1
M\.@I\!^'NF/[/M__ $6M>,_'J&"#XV?"RXM J:D]]Y<A3&YH?,3KWP-S_KVS
M7JPG0QE2>'=%1TE9J^EM=;M]CYRI#%Y;0I8R.)E.[CS1E:S4FEI9)IJY]#S.
MR(6!Z<UX#\$/VB]0^('CO4?#FLVUM;S(':T>W!&_8V&5@2><$$8]#7O1_P!2
M^?2O@#1K*Y\*Z?\ \+$TTND^C^)9(+H+_%$VS'X$ED]_,I95A:.*I5HU%[VB
MB^S=[??L7Q#F.)P&(PLZ+]S5S7>*M?[KW/T&=L#.<5\^?$C]HS4O#?Q@TOPA
MI-K:36\D]M!=RS;BZM(XR%P0.%(ZYY->LW_CC3;+P++XJ^TK+I:6?VU9EZ.F
MS*X^O:OBW2]%N[S4O!WC;4V=]1\1>*0ZENGE+*G3_@1(^BC%/*<%3J.I/$+1
M)I?XK-_@D1Q%FM:BJ-+!RUDU)O\ NW2_%L^^T8LH)JMJ.H1Z;:7%S,X2*%&D
M8GL ,D_I5F(?*N?2O)OVG/%,OAKX5:M':G%]J133X/4^9P_X[ ^*\+#TG7K0
MI+J['UV,Q*PF%G7E]E7_  ,;]GSX_P![\6M9UNQU*"WM)+=5N+1(006A)(.[
M).2,ITQUKW53FOE-_#2?!#XH_"V[#A+>\T\:->N.%:3CYB>G+NI_X#7U3#S&
M*]'-*5&%6-7#JT)+3Y:/\OQ/%X?Q.)J4)4,9*]2#L_1I-?G;Y'(_$OXD:=\,
MO"]QK.I,2J'9#"F-\SG.%7\B<]AGTKQ.P^)?QQ\;6J:UH/A;3[32'^>&.[X>
M1.Q^9U)R,'.!5W]HZ)=>^*OPP\/7/-A<7;331D9#X=.#^ 8?\"KZ(M852!5V
MJ, #"C '':M8RI8'#TYNFIRG=^]LE>VQS5(XC-L;6HJM*G3I67NV3;:3NVT]
M%?8\A^#/QWG\>:S=^&_$&F'0O%%GEGM'!42*,9*@\@C(X[@Y!/;TOQ?J\VA^
M&=6U&W ::TM)9T5AP2JDC/Y"O,_&'PSU.\^.OA/Q?I=M&+2VC>'4)0X5R,,%
MXZMPQ'^17?\ Q"/_ !07B$D'/]GW'7_KFU<V)6'G6ISHJRE:\>SO9K]3MPD\
M92PM>GB7>4&TI;75KI^O0^?/"WQW^,GC+2HM1T;P=8:C8R$JL\;;02.#P9,\
M5MP_$KX[&XB67P%:1Q,ZAF#@D#//_+6N@_9!V#X+:=D@DW%QUZ_ZPU[8/+/3
M:?QKT,9B:&'KU*,</&R;5]?\SR,LP&)Q>%I8F>,G>23M>-OR(S*WV4R?Q;<U
MYK\ /B;JGQ1\/:KJ&J0P6\UKJ$EHB6X(7:JH<G.>?F->G3K_ *-)_NFO!/V-
ML?\ ""^(!_U&IO\ T7%7F4J<)82K4:U3C;YW/=Q->I3S+#48R]V2G?SM:WYG
MO=PQ2&1E^\%)&:\J_9X^*NJ_%CPWJ>HZK;VUO+;7S6JK; A2H1&R<D]V/Y5Z
MK<_ZB7_=/\J^>?V)A_Q;_7?^PL__ *)AJJ%*$L'6J-:IQM\[W(Q>(JT\TPU&
M+]V2G==[6L=5\4O%OQ2T7Q,+?P?X8MM8TD0*QN9I%4B0ELK@NO0!>W>O,[OX
M]?%ZQ\5VGAJX\*Z9'KMY%YT%GOY=?F).X2;?X&X)[5]5%5/:OG#QHH/[8O@H
M<?\ (*?C_@-S7H9=6HU%*$Z,7RQ;OK=V5^YXN=X;$X>4*M+%37/.*MI9*3MI
MH=!X#\;?&#4O%6GVWB3PC::=HTC-]HNHY%9D 0D8 D/5@!T[UWGQ@\97G@'X
M<ZOK]@D4EW9HCHDX)0Y=0<X(/0UV0C&!P*\R_:9Y^"'B?_KE'_Z-2N"G4IXO
M%TDZ:BFTK*_<]JM1JY=EU=JM*<DI-.5KK3R2.H^&?B:Y\8> ]#UJ\5([F^M(
MYY$BSM4LN3C/-<_\8_C%9_"71(KN6)KZ^N6\NULH_O2MW.>P&1^> ,D59^!'
M/P<\(_\ 8-A_]!%>6>*]-3Q-^USH%G>_O;73=,^U10N,KO\ G(/_ 'T5/_ 1
M6U'#TI8RHIKW(<SMY+H<N*QN(IY90E2?[RIRQN^CE:[_ #*J^/?C]>6G]M1>
M$]/CL"OF+9.!YQ3&?NF0-G'; /M7I7P2^-<'Q8L;N.:U?3-9L2JW=E)GC.?F
M7(SC((((!!&#VSZ9%$FS&WKUS7CNA_#'6-%_:,U7Q7;PQP^'KZP\N0JXW/-\
MF<I]5)S]?6J=?#XNE.,J<8-*\6K_ '/N9QPN.RZO2G"M*K&3M).SM=?$K)6L
M^A[1G%>,_M%?&C4/A+I6EG28[:XU*]F<>7<@E1&JY8\$=V7]:]D)"YST'-?-
MFJZ1;_%W]HC7K.9O-T[0-'DLMW55GG4JV/<!W'_ *Y\MITI5G4KJ\(IM_DOQ
M:.S/:]>GAU2PLK5*C44^W5O[DSWKP=XCB\6>&=,U>'/EWMO'< 8Z;E!Q^'2M
MISMC)'6O#OV3]<N)? M]X=OSB_\ #M])9.,\[=V1GZ$LO_ :]P<_NC]*YL91
M^KXB5);)_AT_ ]#+<4\9@J==[M:^O7\3R;X;_%75_%_Q/\;>'KN""*RT20);
MO&I#OEB,L>G;MBO6E^8 U\Z? K)^/WQ7ST\^/_T-Z^C%^Z*WS&E"C64::LN6
M+^](Y,DKU<3AG.J[OFDODI-+\!DC%?:O"/B)\<?$;^-I/!?@+2(]7UJ!=UU<
MS_ZF#@$@G('&1R2.N ":]UGR5X]#7R_\'_$^F^"OCE\1=,\03I8W^H:@9+::
MY(564N[*FX],JZD#OS6N74HR56K*'.X*Z7S2U\D<N>8FI3=##PJ>SC4E9R[:
M7LK[-O2Y;N_C'\5?A5);7GCSP_9W>ARR!'NM-ZQ9]<,1],@9]<\5]$Z'K5KX
MAT>SU.RE6>SNXEFAD4<,K#(-5]<T;3_%.DRV%]!'>6%RNV2)^5=?3^6#VJ[I
M&G6NDZ=!9V,"6]I"NR**(85%'0 "N?%5Z>(@G&FH3ZVV:].YW8#"5\)4DI5G
M4IM:<VK3ZZ]4>1?M@,T?[/\ XF()'S6H./0W,6:_.I)AGKGUYK]%/VQFQ^SW
MXF/^U:?^E45?G_X T"#Q=XKT[2[K4;?2;.>7-Q>W,BQI%$.7.3@9VYQ[D5^F
M<)U(T<NJ3ETDW^"/R'CFA+$9M2IQW<4OQ9Z5\'/A=X[U.XT_Q9H/A*'7K*VF
M;R1=W$<<3R*<!MK."VT]#TR.M?2"^+OVA!_S(.DC_M\BX_\ (M>C^&_B'\./
M"^B66E:?XFT*VLK2)8HHH[Z+"J!@?Q=??WK6_P"%Q>!ST\6:-_X&Q_\ Q5?*
MX_-<1C:KG4PR:6UU+;[S['+,CPF74%"EC'%O>SC:_P U<\G3QA^T&.O@/2_P
MNXO_ ([3_P#A,/V@!_S(NF?A=Q?_ !VO5Q\7_!!Z>*]&_P# V/\ ^*H/Q>\$
MC_F:M&/TO8O_ (JO-^L3_P"@2/\ X#+_ #/6>#IO_F83_P# H?Y'D=SXY^.]
MI;R37'@S28(8U+R227L2JBCJ2?-X Y)-?%_QP^-&L_&7Q%;W>IM%%;6"-!;6
M]LQ\K.?G?D\EL#GT QU->Z_MA_M,P^((Y? _A*]$M@W&J:A;N"DP_P">"-SQ
M_>(] /6OD$Y4$XSC) QGMTK]$R'!)4_K=:C&$NED[V\[MGYMGV-DJKP=#$3J
M1ZW:M?RLD?J/^R</^,>_!P/!^S.?_(KUYW^T9<:U:_''P-+X=M([[6UMI/LM
MO*0$=LG()) Z9[]J]I^"7AR;PC\)?">D3IY=Q::="LRGL^T%_P!2:\Q^*H)_
M:<^&G'2*4_\ H=?!82HGF-:JE=>^_P &?H.;46\HH46[.]-76ZU11N-6_:&U
MB'[&F@:7H_F?+]L$L3&,=SCS&_\ 037H_P #/A%_PJS1[MKRZ_M'7=1D\V^O
M.?F/.%!/. 2QR>26/X>F*#@<T_'I7F5LPG5I.C"$81>_*K7]=SV<)DU/#UEB
M*E6522VYG>WI9)'@_P"V2?\ BTZ#_J(0_P#H+USEC^R?J-S:0RCX@ZV@D0/M
M#O@9'^_71?MDG_BU"?\ 81A_]!:O:]%;_B66G/\ RQ3^5>C#&U\)E]/V,K7E
M+MV7<\6IEF&S#.:_UB+=H0MJUUEV9\5_'OX)77PR\-Z=?3^*=1UQ9[U8!#>.
MQ5#L8[@"QY^7'XFOMRW;;!&3_<'\J^>OVV#_ ,4%H8/_ $%4_P#14M?02-LM
M8C_LK_*L\PQ%3%8*A4JN[O+]#;)\)1P.:8NE05HVAW??N?.G[6OBNS.H^#O#
M%[=+::?=7JWFH3-D[($;;R!SSN;''\-0?&_XP_#GQ]\+=5T6QU^":^\I9+6,
MV\JYD0[@ 2F!G!&??THT'0;7XQ?M%>+K_5K>+4=#T&%=.@MYU#(9,X.0>N&$
MI_$5Z]/\$? PA8KX5TL'''^CK_A78ZV$P:H4ZJESP2EI:UWKU\K'E+#YCF<L
M77P[AR5&XKF3O:.FEGWNR'X$^,%\9_"S0=09LSB 6\^3D^9'\C'\=N?H17)?
MM@-_Q9:]S]W[7;Y_[^"L+]F.]F\*^)?&_@2Y!3^S;YKBV#=6C8[?Y"-O^!UL
M_M@MCX*WP_Z>K?\ ]&"N>%)4<WA&.SDFO1ZH[IXB6)X;J2G\2@XOU6C_ "//
MCXS^-O@[X>V^J?V7I!T*ULHG21 ))!"% #%0W.!R?3GTKI?@1X"O?'.MV7Q.
M\4:S%K6H2Q?Z## "$M>H((Z KEA@#KDG)Z>R>"["*_\ AWHEM.BRPR:;#&\;
M<A@8@""/H:\4^%MY-\$OB[J/P^OY)?[$U5S=Z/(_W03GY ?< K]5']ZNCZS]
M8HUH481A-=EO'JOU\T<$<#]3Q&%JXFI*=*5OB=U&?V7T5NBOLSZ1F&V%OH:^
M9?V?/"EOXU^%WC[1;I5:*\U6XCRPSM;8F&'NIP?PKZ9E</$P']W->"?LAC/A
MGQ4O0G6YL'_@"5Y>$J2IX2M..Z</S9]!F5*-;,<-3FKIQFOP1X=;^-->U;P+
M8?!][=DUL:M]BD/\(@5L[2?]E\_\!3WKUSXZ:%:^%[GX/:59H(K:SU:&&-0.
MP:,<_E7J%K\$=#L_B?/XYC,_]J3 YA++Y*L5"%P-N=V!CDX^8UP7[3@QXJ^%
MH/!_MV,?^/QU[4<=2Q6)IQHJRM*3_P 3B[_\ ^7GE.(P.!K5,4^:5X1C_@4E
M;YOJ?0$9P@],5\S?M$>+-(E^,/@?2-;U!+'1-,<:G>.5+@ODF-2JY/\ RSQ]
M'KZ5+[(@WI7S5\)/"VE?&+XC^/?%>MV<.K6'VQ;*Q2= R!4&,@'_ &0G_?1]
M:\?*_9TY5,15ORP73>[T5OQ9]+G[JUZ=' X>W-4DM]K1]YWMK;1(SOVBOBSX
M#^('@$0Z1K\=QK5E<Q75H@AE4E@V",E<#Y6)_ 5]$?#KQ3'XP\$:-K,9!%Y:
MQR''9L#<I]PP(_"L#5?@5X&N-.N84\-:="TD;()$@ 9<@C(/J*X+]D;798O#
M.M^$[IC]NT"_DB*-U",S<_\ ?:R?I737^KXC ?[-S?NW]JVTM.GFOQ./"?7,
M'FR^NN/[Z-O=OO'76_6S_ J?',$_M!_"GT\US_X\M?14+ IP>*^=/VJ;*\T'
M5?!?CBT@:XBT.[Q<*O969&&3V'RE<GNPKUCPM\6_"?B30X]1M-;M$@*!F6>9
M4>/CD,">,5SXJE.KA*%2FKI)I^3NW^IU9?B*6'S+&4:TN63:DK]5RI77S1V+
M7$2,%+J"> .]<_\ $5@W@'Q"1S_Q+[C_ -%M7A1\5CXN?M*Z'_PC\LESHGAZ
M%WN;J-B(78AOP/S% #WPW4#->Y?$4[? 7B+/_0/N#_Y#:N6IA986K24WJ[.W
M;7_+4[X8^.88;$2IKW8W2?>RW7ST/E3X'_ &\^(?P_M-8A\7ZIHZ22R)]EMG
M8(-K$9 W <]>E>S_  U_9]O/A_XL@U>;Q=JFLI'&Z?9KEV,9R,9/S'D=N*YO
M]ESXB>&?#7PCT^QU77=/T^Z6>=C#<7"(P!<X."0>E>O)\8?!+LJKXITIF8@
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M5A=;.ZTN>W]JY3QE\.-'\=WND76J1RO+I5P+JU,<A7;("#D^O0<&O//^&O\
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MG3DFNR9ZE?-,GQ--TJU6$HOHVB?PQ^R=X#\,:E'?"SGU&6-@R+>2[D!'0E0
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M5"]T33]29&NK*WN67A3+$K$?3-7^>U->58\;F SP,UYB;3NCUI14U:2N9?\
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M%D1P-K Y&1CTI^TJ6O=A["C_ "K[C+_X1/1/^@39?^ Z?X4?\(GHG_0)LO\
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MIDLVM7&GV5U]BO?$%IICRZ7:S9P5>X''!X) (]ZY3XB2V*_MT^%CIYB_MA/
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MY4;1_=%5]8K:^]ON')'30XCP'\)=&^'WBOQIX@TU[HWOBN\BOK\3R[D$B)L
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M,,C'0T44+<"2 81?I4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
